13
1 © MorphoSys AG | Meet the Team | June 25, 2019 Nuwan Kurukulasuriya, Senior Vice President Head of Global Medical Affairs Meet the Team | June 25, 2019
1© MorphoSys AG | Meet the Team | June 25, 2019
Nuwan Kurukulasuriya, Senior Vice President Head of Global Medical Affairs
Meet the Team | June 25, 2019
2© MorphoSys AG | Meet the Team | June 25, 2019
This presentation includes forward-looking statements.
This communication contains certain forward-looking statements concerning the MorphoSys group of companies, including its financial guidance for 2019,
the commencement, timing and results of clinical trials and release of clinical data both in respect of its proprietary product candidates and of product
candidates of its collaborators, the development of commercial capabilities, in particular with respect to tafasitamab (MOR208) and the transition of
MorphoSys to a fully integrated biopharmaceutical company, interaction with regulators, including the potential approval of MorphoSys’s current or future
drug candidates, including discussions with the FDA regarding the potential approval to market tafasitamab, the expected time of launch of tafasitamab,
and expected royalty and milestone payments in connection with MorphoSys’s collaborations. The forward-looking statements contained herein represent
the judgment of MorphoSys as of the date of this release and involve known and unknown risks and uncertainties, which might cause the actual results,
financial condition and liquidity, performance or achievements of MorphoSys, or industry results, to be materially different from any historic or future
results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if
MorphoSys’s results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such
forward-looking statements, they may not be predictive of results or developments in future periods. Among the factors that may result in differences are
that MorphoSys’s expectations regarding its 2019 results of operations may be incorrect, MorphoSys’s expectations regarding its development programs
may be incorrect, the inherent uncertainties associated with competitive developments, clinical trial and product development activities and regulatory
approval requirements (including that MorphoSys may fail to obtain regulatory approval for tafasitamab and that data from MorphoSys’s ongoing clinical
research programs may not support registration or further development of its product candidates due to safety, efficacy or other reasons), MorphoSys’s
reliance on collaborations with third parties, estimating the commercial potential of its development programs and other risks indicated in the risk factors
included in MorphoSys’s Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission. Given these uncertainties, the
reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of
publication of this document. MorphoSys expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any
change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may
affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or
regulation.
The compounds discussed in this slide presentation are investigational products being developed by MorphoSys and its partners and are not currently
approved by the U.S. Food and Drug Administration (FDA), European Medicine Agency (EMA) or any other regulatory authority (except for
guselkumab/Tremfya®). Any shown cross-trial comparison between MorphoSys-own investigational products and literature data have significant
limitations. Such data comparisons have been prepared at the request of, and for the sole benefit of, the investor community.
3
Executing a multi-stakeholder medical engagement strategy
© MorphoSys AG | Meet the Team | June 25, 2019
Medical Affairs
Nuwan Kurukulasuriya
Senior Vice President
Head of Global Medical Affairs
20 years of academic, medical affairs and clinical
development experience
Prior positions at Johnson & Johnson, EMD Serono/Merck
KGaA, Biogen and Shire leading medical affairs teams and
providing portfolio-wide oversight of launch strategies
As Head of Medical Research and RWE and member of
Biogen’s Global Medical Affairs Leadership Team,
co-engineered Medical-Marketing-Market Access launch
strategies; successfully launched Tecfidera®, now
generating $4bn in annual revenues
As VP Head US Medical Affairs at Shire led large teams
across multiple therapeutic areas including hematology,
oncology, immunology, neurology, ophthalmology and
rare diseases
4© MorphoSys AG | Meet the Team | June 25, 2019
We are building a strong patient-centric medical
organization as a conduit to the oncology community
5
Launching tafasitamab to become the potential new standard of care in r/r DLBCL
© MorphoSys AG | Meet the Team | June 25, 2019
Medical Affairs Strategy
Evidence-based Scientific and Value Narrative
Differentiating on long-term clinical and cost effectiveness
Launching investigator and company sponsored studies
Outreach and Awareness
Dynamic mapping, field-validation and engagement of KOLs
Dual academic medical center and community focus
>200
Informing Real World Clinical Practice
Optimized treatment sequencing within DLBCL
Improve patient outcomes
6
Multi-stakeholder, multi-channel engagement
© MorphoSys AG | Meet the Team | June 25, 2019
Communicating with Impact
7
May 2019 June 2019
ISPORASCO
EHA
ICML
Poster + Dr Johannes Dull,
L-MIND data showcase
Poster:
MOR208 + LEN
event simulation model
ICML L-MIND
platform presentation
Emphasizing clinical and cost effectiveness
© MorphoSys AG | Meet the Team | June 25, 2019
Relaying the Tafasitamab Value Story
8
Medical affairs immersive booth
Competitor and congress intelligence to inform insights
Poster and oral presentations
Multichannel social media communication campaign
Post-congress materials
for enduring resources
Pre-congress materials
+ teaser campaign
Engagement with third party channels
Leaving an impression – evolving our creative theme
Real-time reactions to data by KOLs
Connecting with customers via digital, multi-media science-campaign
Building a Runway to Launch Excellence
© MorphoSys AG | Meet the Team | June 25, 2019
9
Hematologists/oncologists, patients and caregivers are key influencers on treatment
© MorphoSys AG | Meet the Team | June 25, 2019
The DLBCL Care Community
Stakeholders Across the DLBCL Care Community
Payer
Social
worker
NurseTransplant
physician
Internal medicine
physician
Hematologist/
oncologist
Patient Caregiver
Office
managers
Pathway
developers
Patient advocacy
groups
Pro
vid
er
Pati
ent
Payer
& P
olicy
10
1) IQVIA for MorphoSys: U.S. Patient Journey, June 2018 KOL – Key opinion leader
Strategy to create awareness and establish extensive HCP and KOL network
© MorphoSys AG | Meet the Team | June 25, 2019
Targeted U.S. Medical Affairs Outreach
Top 10 States
Texas Pennsylvania
California Illinois
Florida New Jersey
New York Arizona
Ohio Michigan
Treated Patient Range # of States
≥560-2,100 10
≥370-560 9
≥210-370 11
≥70-210 10
≥1-70 12
HCP Heat Map1)
56% of treating physicians are
located in top 10 U.S. states
11
1) IQVIA for MorphoSys: U.S. Patient Journey, June 2018
Strategy to reach majority of r/r DLBCL patients1)
© MorphoSys AG | Meet the Team | June 25, 2019
Targeted U.S. Medical Affairs Outreach
50%25%0%
75%
100%
100%
25%
50%
0%
75%Num
ber
of
DLBCL
pati
ents
in t
he U
.S.
[%]
Number of hematologists/oncologists in the U.S. [%]
~1,300
hem/oncs
~2,000
hem/oncs
~2,400
hem/oncs
~1,100
hem/oncs
Focus on top ~2,400
hematologist/oncologists
covers ~75% of all DLBCL patients
12
Working toward a potential paradigm shift driven by strong clinically data
© MorphoSys AG | Meet the Team | June 25, 2019
Access Through Medical Affairs
Pre-launch scientific engagement of key opinion
and thought leaders
Best balance academic medical center vs.
community oncology engagement
Partner with advocacy groups to elevate
awareness of ongoing clinical development
Dynamic field mapping of national and regional
patient advocacy groups
Integrated HEOR evidence generation to support
tafasitamab value story
Develop budget impact model, cost efficiency
model, network meta analyses mixed treatment
comparisons and patient preference study
Together with access and policy teams plan joint
interactions with CMS, Medicare Part B, Medicare
Advantage, IDNs and other payers
Clear and easily understandable value
proposition
Providers Patients
Payers Policy
HEOR - Health Economic and Outcomes Research CMS – Centers for Medicare and Medicaid Services IDN – Integrated Delivery Network
13© MorphoSys AG | Meet the Team | June 25, 2019
Summary
Clear understanding of the DLBCL stakeholder landscape
Compelling and competitive scientific-value narrative
Strong, diverse and agile Medical Affairs organization
SUMMARY
